Expression of the Bcl-3 proto-oncogene suppresses p53 activation

  1. David Kashatus1,2,
  2. Patricia Cogswell2, and
  3. Albert S. Baldwin1,2,3,4
  1. 1Curriculum in Genetics and Molecular Biology, 2Lineberger Comprehensive Cancer Center, and 3Department of Biology, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, USA

Abstract

While Bcl-3 expression in cancer was originally thought to be limited to B-cell lymphomas with a 14;19 chromosomal translocation, more recent evidence indicates that expression of this presumptive oncoprotein is significantly more widespread in cancer. However, an oncogenic role for Bcl-3 has not been clearly identified. Experiments presented here indicate that Bcl-3 is inducible by DNA damage and is required for the induction of Hdm2 gene expression and the suppression of persistent p53 activity. Furthermore, constitutive expression of Bcl-3 suppresses DNA damage-induced p53 activation and inhibits p53-induced apoptosis through a mechanism that is at least partly dependent on the up-regulation of Hdm2. The results provide insight into a mechanism whereby altered expression of Bcl-3 leads to tumorigenic potential. Since Bcl-3 is required for germinal center formation, these results suggest functional similarities with the unrelated Bcl-6 oncoprotein in suppressing potential p53-dependent cell cycle arrest and apoptosis in response to somatic hypermutation and class switch recombination.

Keywords

Footnotes

  • Supplemental material is available at http://www.genesdev.org.

  • Article published online ahead of print. Article and publication date are at http://www.genesdev.org/cgi/doi/10.1101/gad.1352206.

  • 4 Corresponding author. E-MAIL abaldwin{at}med.unc.edu; FAX (919) 966-0444.

    • Accepted November 17, 2005.
    • Received July 5, 2005.
| Table of Contents

Life Science Alliance